Figure 1.
Distinct nuclear immunoreactivity for MIB-1 positive (>20%) in ER negative breast cancer (×100 magnification).
Figure 2.
Immunohistochemical stain for ER in invasive breast carcinoma showing strong nuclear positivity (×200 magnification).
Figure 3.
Immunohistochemical stain showing negative ER immunostaining in invasive breast carcinoma (×200 magnification).
Table 1.
Clinical outcome of ER-negative tumor cases (within 0 to 5 years follow up) in relation with morphological and clinicopathological data.
Figure 4.
C-erbB2 overexpression shows strong positivity (3+) on the cell membrane by immunohistochemistry (×200 magnification).
Table 2.
Significant correlation between tumor staging and tumor size, tumor grade, lymph node metastases in ER-negative tumor.
Table 3.
Significant correlation between axillary lymph node metastases and tumor margin in ER-negative tumor.
Table 4.
Correlation between MIB-1 status with clinicopathological findings and morphologic features.
Table 5.
Frequency table of clinicopathological data and morphologic features of triple negative breast tumor.
Table 6.
Correlation between tumor grade and menopausal status, tumor size, lymph node metastases in MIB-1 triple negative breast cancers.